Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT06439888

Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer (LySATRA)

Pan-lesions SBRT Combined With Lymphocyte Support Through ATRA-driven Blockade of MDSC in Patients With Oligo-metastatic Solid Cancer

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Conditions Oligometastatic Disease Solid Tumor, Adult

Interventions Stereotactic Body Radiation Therapy all-trans retinoic acid

Updated 4 times since 2024 Last updated: Nov 24, 2025 Started: Jul 11, 2024 Primary completion: Sep 30, 2026 Completion: Jan 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Oligometastatic Disease and Solid Tumor, Adult, this trial is actively recruiting participants. The trial is conducted by Gustave Roussy, Cancer Campus, Grand Paris and has accumulated 4 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gustave Roussy, Cancer Campus, Grand Paris

Data source: Gustave Roussy, Cancer Campus, Grand Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lyon, France
• Villejuif, France